The Experts below are selected from a list of 148065 Experts worldwide ranked by ideXlab platform
Gaurav Varma - One of the best experts on this subject based on the ideXlab platform.
-
dose adjusted epoch rituximab therapy in primary mediastinal b cell Lymphoma
The New England Journal of Medicine, 2013Co-Authors: Kieron Dunleavy, Julie Hessler, Cliona Grant, Ranjana H. Advani, Stefania Pittaluga, George E. Wright, Clara C. Chen, Lauren S. Maeda, Seth M Steinberg, Gaurav VarmaAbstract:BackgroundPrimary mediastinal B-Cell Lymphoma is a distinct subtype of diffuse large-B-Cell Lymphoma that is closely related to nodular sclerosing Hodgkin's Lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy. MethodsWe conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal B-Cell Lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. ResultsThe patients had a median age of 30 years (range, 19 to 52) and a media...
-
dose adjusted epoch rituximab therapy in primary mediastinal b cell Lymphoma
The New England Journal of Medicine, 2013Co-Authors: Kieron Dunleavy, Julie Hessler, Cliona Grant, Ranjana H. Advani, Stefania Pittaluga, George E. Wright, Clara C. Chen, Lauren S. Maeda, Seth M Steinberg, Gaurav VarmaAbstract:BackgroundPrimary mediastinal B-Cell Lymphoma is a distinct subtype of diffuse large-B-Cell Lymphoma that is closely related to nodular sclerosing Hodgkin's Lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy. MethodsWe conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal B-Cell Lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. ResultsThe patients had a median age of 30 years (range, 19 to 52) and a media...
Fuat Oduncu - One of the best experts on this subject based on the ideXlab platform.
-
chemically linked phage idiotype vaccination in the murine b cell Lymphoma 1 model
Journal of Translational Medicine, 2013Co-Authors: Tim Roehnisch, Cornelia Then, Wolfgang Nagel, Christina Blumenthal, Todd A Braciak, Mariel Donzeau, Thomas Bohm, Carole Bourquin, Fuat OduncuAbstract:B cell malignancies are characterized by clonal expansion of B cells expressing tumor-specific idiotypes on their surface. These idiotypes are ideal target antigens for an individualized immunotherapy. However, previous idiotype vaccines mostly lacked efficiency due to a low immunogenicity of the idiotype. The objective of the present study was the determination of the feasibility, safety and immunogenicity of a novel chemically linked phage idiotype vaccine. In the murine B cell Lymphoma 1 model, tumor idiotypes were chemically linked to phage particles used as immunological carriers. For comparison, the idiotype was genetically expressed on the major phage coat protein g8 or linked to keyhole limpet hemocynanin. After intradermal immunizations with idiotype vaccines, tolerability and humoral immune responses were assessed. Feasibility and tolerability of the chemically linked phage idiotype vaccine was demonstrated. Vaccination with B cell Lymphoma 1 idiotype expressing phage resulted in a significant survival benefit in the murine B cell Lymphoma 1 protection model (60.2 ± 23.8 days vs. 41.8 ± 1.6 days and 39.8 ± 3.8 days after vaccination with wild type phage or phosphate buffered saline, respectively). Superior immunogenicity of the chemically linked phage idiotype vaccine compared to the genetically engineered phage idiotype and keyhole limpet hemocynanin-coupled idiotype vaccine was demonstrated by significantly higher B cell Lymphoma 1 idiotype-specific IgG levels after vaccination with chemically linked phage idiotype. We present a novel, simple, time- and cost-efficient phage idiotype vaccination strategy, which represents a safe and feasible therapy and may produce a superior immune response compared to previously employed idiotype vaccination strategies.
Stefania Pittaluga - One of the best experts on this subject based on the ideXlab platform.
-
dose adjusted epoch rituximab therapy in primary mediastinal b cell Lymphoma
The New England Journal of Medicine, 2013Co-Authors: Kieron Dunleavy, Julie Hessler, Cliona Grant, Ranjana H. Advani, Stefania Pittaluga, George E. Wright, Clara C. Chen, Lauren S. Maeda, Seth M Steinberg, Gaurav VarmaAbstract:BackgroundPrimary mediastinal B-Cell Lymphoma is a distinct subtype of diffuse large-B-Cell Lymphoma that is closely related to nodular sclerosing Hodgkin's Lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy. MethodsWe conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal B-Cell Lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. ResultsThe patients had a median age of 30 years (range, 19 to 52) and a media...
-
dose adjusted epoch rituximab therapy in primary mediastinal b cell Lymphoma
The New England Journal of Medicine, 2013Co-Authors: Kieron Dunleavy, Julie Hessler, Cliona Grant, Ranjana H. Advani, Stefania Pittaluga, George E. Wright, Clara C. Chen, Lauren S. Maeda, Seth M Steinberg, Gaurav VarmaAbstract:BackgroundPrimary mediastinal B-Cell Lymphoma is a distinct subtype of diffuse large-B-Cell Lymphoma that is closely related to nodular sclerosing Hodgkin's Lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy. MethodsWe conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal B-Cell Lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. ResultsThe patients had a median age of 30 years (range, 19 to 52) and a media...
-
t cell histiocyte rich large b cell Lymphoma
Haematologica, 2010Co-Authors: Stefania Pittaluga, Elaine S JaffeAbstract:T-cell/histiocyte-rich large B-Cell Lymphoma (THRLB-CL) can be used as a paradigm to highlight the difficulties in defining specific subtypes of diffuse large B-Cell Lymphoma. Since the first recognition of certain large B-Cell Lymphomas in which the tumor cell content was dramatically outnumbered
Kieron Dunleavy - One of the best experts on this subject based on the ideXlab platform.
-
dose adjusted epoch rituximab therapy in primary mediastinal b cell Lymphoma
The New England Journal of Medicine, 2013Co-Authors: Kieron Dunleavy, Julie Hessler, Cliona Grant, Ranjana H. Advani, Stefania Pittaluga, George E. Wright, Clara C. Chen, Lauren S. Maeda, Seth M Steinberg, Gaurav VarmaAbstract:BackgroundPrimary mediastinal B-Cell Lymphoma is a distinct subtype of diffuse large-B-Cell Lymphoma that is closely related to nodular sclerosing Hodgkin's Lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy. MethodsWe conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal B-Cell Lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. ResultsThe patients had a median age of 30 years (range, 19 to 52) and a media...
-
dose adjusted epoch rituximab therapy in primary mediastinal b cell Lymphoma
The New England Journal of Medicine, 2013Co-Authors: Kieron Dunleavy, Julie Hessler, Cliona Grant, Ranjana H. Advani, Stefania Pittaluga, George E. Wright, Clara C. Chen, Lauren S. Maeda, Seth M Steinberg, Gaurav VarmaAbstract:BackgroundPrimary mediastinal B-Cell Lymphoma is a distinct subtype of diffuse large-B-Cell Lymphoma that is closely related to nodular sclerosing Hodgkin's Lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy. MethodsWe conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal B-Cell Lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. ResultsThe patients had a median age of 30 years (range, 19 to 52) and a media...
Tim Roehnisch - One of the best experts on this subject based on the ideXlab platform.
-
chemically linked phage idiotype vaccination in the murine b cell Lymphoma 1 model
Journal of Translational Medicine, 2013Co-Authors: Tim Roehnisch, Cornelia Then, Wolfgang Nagel, Christina Blumenthal, Todd A Braciak, Mariel Donzeau, Thomas Bohm, Carole Bourquin, Fuat OduncuAbstract:B cell malignancies are characterized by clonal expansion of B cells expressing tumor-specific idiotypes on their surface. These idiotypes are ideal target antigens for an individualized immunotherapy. However, previous idiotype vaccines mostly lacked efficiency due to a low immunogenicity of the idiotype. The objective of the present study was the determination of the feasibility, safety and immunogenicity of a novel chemically linked phage idiotype vaccine. In the murine B cell Lymphoma 1 model, tumor idiotypes were chemically linked to phage particles used as immunological carriers. For comparison, the idiotype was genetically expressed on the major phage coat protein g8 or linked to keyhole limpet hemocynanin. After intradermal immunizations with idiotype vaccines, tolerability and humoral immune responses were assessed. Feasibility and tolerability of the chemically linked phage idiotype vaccine was demonstrated. Vaccination with B cell Lymphoma 1 idiotype expressing phage resulted in a significant survival benefit in the murine B cell Lymphoma 1 protection model (60.2 ± 23.8 days vs. 41.8 ± 1.6 days and 39.8 ± 3.8 days after vaccination with wild type phage or phosphate buffered saline, respectively). Superior immunogenicity of the chemically linked phage idiotype vaccine compared to the genetically engineered phage idiotype and keyhole limpet hemocynanin-coupled idiotype vaccine was demonstrated by significantly higher B cell Lymphoma 1 idiotype-specific IgG levels after vaccination with chemically linked phage idiotype. We present a novel, simple, time- and cost-efficient phage idiotype vaccination strategy, which represents a safe and feasible therapy and may produce a superior immune response compared to previously employed idiotype vaccination strategies.
